(Bloomberg) -- Carl Icahn has decided not to launch a fresh proxy fight at DNA sequencing company Illumina Inc. this year, a person familiar with the matter said.Most Read from BloombergStock Traders Bracing for Worst Shrug Off Hot CPI: Markets WrapOne of the Most Infamous Trades on Wall Street Is Roaring BackUS Core Inflation Tops Forecasts Again, Reinforcing Fed CautionChina Has Never Canceled This Many Shipments of US WheatNY Says Trump Should Post Full Bond During Fraud Case AppealThe activi